OncLive TV

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the management of endometrial cancer.

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses the importance of multidisciplinary care in the treatment of patients with head and neck cancer.

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center discusses symptom management in patients with multiple myeloma.

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses how to determine patients with high-risk chronic lymphocytic leukemia (CLL).

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significant results of the PROTECT study for patients with prostate cancer.

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center discusses areas of research for patients with pancreatic cancer.

Paul B. Chapman, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, professor of medicine at the Weill Cornell Medical College, discusses targeted treatments for non-traditional mutations in melanoma.

Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.

Alicia Morgan, MD, Mather Hospital, discusses the role of PARP inhibitors for patients with prostate cancer.

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses challenges facing chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

Martee L. Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses DNA mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) testing for patients with endometrial cancer.

Leonard Saltz, MD, executive director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses the option of FOLFIRINOX for the treatment of patients with metastatic colorectal cancer.

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses disparities in the treatment of lung cancer.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in liver cancer.

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment in the neoadjuvant setting for patients with kidney cancer.

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses choosing a checkpoint inhibitor in bladder cancer.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses choosing treatments for patients with multiple myeloma.

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses clinical trials in neoadjuvant HER2 breast cancer.

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of afatinib (Gilotrif) for the frontline treatment of patients with metastatic non

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the role of immunotherapy for patients with prostate cancer.

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the AIM2CERV trial for patients with cervical cancer.

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses when to conduct microsatellite instability (MSI) testing for patients with gastric cancer.

Jennifer Eads, MD, assistant professor, senior clinical instructor, department of medicine, University Hospitals Cleveland Medical Center, discusses the classification of gastrointestinal neuroendocrine tumors.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with mCRPC.

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses the FDA approval of olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic settings.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses remaining questions with rituximab (Rituxan) maintenance for patients with mantle cell lymphoma (MCL).

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses the management of BRCA1/2 mutations in patients with ovarian cancer.

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the long-term benefits of the CheckMate-214 study in patients with renal cell carcinoma (RCC).

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses tailoring treatment to individual patients with prostate cancer.